Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Presence of anti-acetylcholine receptor (anti-AChR) antibodies is highly specific for myasthenia gravis (MG). These antibodies are detected in 85%–95% of sera from patients with generalized MG and 40%–70% of patients with ocular MG.1
An increasing incidence of MG, especially in the elderly population, has been described in Japan, the United Kingdom, and Denmark.2,–,4 Recent studies have also focused on the epidemiology of anti-AChR antibody seropositivity as a surrogate marker of MG.4,–,6 The Neuro-Immunology Laboratory at the University of British Columbia is the sole laboratory in British Columbia (BC), Canada, offering anti-AChR antibody testing for clinical diagnosis.
The aims of this study were to evaluate the incidence and epidemiologic characteristics of anti-AChR antibody seropositivity in BC and to examine changes in incidence over time.
Methods.
We performed a population-based study of the incidence of anti-AChR antibody-seropositivity in BC for the 25-year period of January 1, 1984, to December 31, 2008. Incident cases were ascertained by retrospectively identifying all first-time seropositive tests. A positive anti-AChR antibody test …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Association of Neurofilament Light With the Development and Severity of Parkinson Disease
Dr. Rodolfo Savica and Dr. Parichita Choudhury
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Brief Communications
Incidence of myasthenia gravis in the Emilia-Romagna region: A prospective multicenter studyEmilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology* et al.Neurology, July 01, 1998 -
Article
Clinical and therapeutic features of myasthenia gravis in adults based on age at onsetElena Cortés-Vicente, Rodrigo Álvarez-Velasco, Sonia Segovia et al.Neurology, February 18, 2020 -
Articles
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitalsA. Alshekhlee, J. D. Miles, B. Katirji et al.Neurology, May 04, 2009 -
Article
High κ free light chain is a potential biomarker for double seronegative and ocular myasthenia gravisAdi Wilf-Yarkoni, Yifat Alkalay, Talma Brenner et al.Neurology: Neuroimmunology & Neuroinflammation, July 14, 2020